Chikungunya (CHIK) is a vector-borne disease caused by infection with the chikungunya virus (CHIKV), a ribonucleic acid (RNA) arbovirus from the family *Togaviridae* and genus *Alphavirus* ([@B1], [@B2]). Transmission occurs through two mosquito species, *Aedes aegypti* and *Aedes albopictus* ([@B3], [@B4]). The virus was initially isolated in Tanzania in 1952 and named "chikungunya" after the Makonde word meaning "that which bends up," referring to symptoms experienced by affected individuals ([@B5]).

Infection has occurred mainly in periodic outbreaks in Africa and Asia. In 2006, there were two major epidemics with high attack rates, including over 1 million cases in India and approximately 300 000 cases in Reunion Island, a French territory in the Indian Ocean ([@B3], [@B6]). In December 2013, however, cases of CHIKV infection on the Caribbean island of St. Martin triggered the Pan American Health Organization (PAHO) to release the first alert about CHIKV in the Region of the Americas ([@B2], [@B7], [@B8]). Since then, local transmission has been confirmed in 43 countries and territories of the Region, with over 1.3 million suspected cases ([@B2]).

In February 2014, cases of a febrile syndrome accompanied by arthralgia were reported in the town of San Gregorio de Nigua in the San Cristóbal province of the Dominican Republic. This town is adjacent to a large commercial port that receives daily imports from overseas. These cases, confirmed to be CHIKV infection by the United States Centers for Disease Control and Prevention (CDC; Atlanta, Georgia, United States) in April 2014, marked the beginning of an epidemic in the Dominican Republic. Over 530 000 suspected cases were reported in the Dominican Republic from 2013 -- 2014 ([@B7], [@B9]). In 2015, however, newly suspected cases dropped to just 67 ([@B7]), a clear decline from the recent peak of the epidemic. Due to the cyclic nature of epidemics and the inability to be re-infected with CHIKV, it is not yet clear if the virus will remain endemic in the country. Therefore, monitoring and surveillance remain crucial, as well as ongoing evaluation of the infestation indexes of *Aedes* mosquitoes ([@B4], [@B9], [@B10]). According to the national CHIKV preparation and response plan ([@B11]), the first entomological studies showed a house index of 0.2 -- 2.5 and elevated infestation in water containers used for household consumption.

Prior to symptom onset, CHIKV has both an "extrinsic incubation period" in which it replicates in the salivary glands of the mosquito (average 10 days) and an "intrinsic incubation period" in the human host following the mosquito bite (average 3 -- 4 days; range = 2 -- 10 days) ([@B3]). In the acute phase, symptoms often begin abruptly with high fever and arthralgia ([@B3], [@B12]). In severe cases, joint inflammation can lead to swelling, redness, and limited movement, necessitating rest and absence from daily activities. Initial effects last approximately 3 -- 10 days and can also be accompanied by, but not limited to: headache, myalgia, edema, nausea, vomiting, chills, and conjunctivitis ([@B3]).

In the majority of cases, the acute phase duration is 2 -- 5 days ([@B13]). After a sub-acute or convalescent phase of up to 12 weeks in which there is no viremia, chronic effects often follow. Common chronic manifestations include degenerative disc disease, arthritis, depression, anxiety or panic disorders, and visual impairment ([@B14]). Continued inflammation can lead to recurrence of arthralgia in affected joints ([@B15], [@B16]). The chronic pain after CHIKV infection can be greater than during the acute disease, resulting in a significant burden on quality of life ([@B17]). These effects have been shown to continue for up to 5 years ([@B18]). In two studies from Reunion Island, 60% -- 63% of patients had persistent arthralgia 1.5 -- 3 years after the epidemic, with about half reporting a negative impact on quality of life ([@B17], [@B19]). Several common risk factors for chronic arthralgia have been highlighted, including age \> 45 years, intensity of acute pain, and past medical history of arthralgia ([@B20]--[@B22]).

Much of the current literature has focused on describing barriers and improvements to treatment, control, surveillance, and prevention of CHIKV infection in the Americas ([@B3], [@B4], [@B9], [@B10]), but is insufficient in highlighting the impact of infection on specific populations. This paper will attempt to further characterize the recent epidemic in the Dominican Republic and the clinical manifestations of CHIKV infection by observing the specific impact on personnel at the *Universidad Autónoma de Santo Domingo* (Autonomous University of Santo Domingo; Santo Domingo, Dominican Republic UASD). Additionally, it will look at particular factors related to prevalence of clinical symptoms, with an emphasis on chronic effects. Learning more about the behavior of these manifestations may help the medical and public health communities to better develop CHIKV prevention and treatment strategies for the Americas and limit the burden of the chronic phase of infection.

MATERIALS AND METHODS
=====================

A descriptive cross-sectional study was conducted to observe the prevalence, impact, and clinical manifestations of CHIKV infection among professors and staff in a university setting following the outbreak in 2014. The Institutional Review Board at Columbia University Medical Center (New York City, New York, United States) approved all study protocols. Prior to participation, all subjects were informed of the study objectives and scope, and assured that withdrawal would be permitted at any time. All participants provided informed consent prior to the interviews; data were anonymous and confidential.

Study setting
-------------

All research was carried out at UASD, the largest and only public university in the Dominican Republic. Surveys were completed through interviews performed by researchers and students on the main campus in Santo Domingo during the fall term of 2014. Analysis was performed at the Office of Health Sciences Research during the summer term of 2015.

Sample size and sampling procedure
----------------------------------

Two separate sample sizes (professors and staff) were used. The university staff population was 3 348 and the professor population was 2 969. The appropriate probabilistic sample size was calculated using Epi Info™ version 7.1.3 (CDC, Atlanta, Georgia, United States), separately for each group (professors and staff), based on a 95% Confidence Interval (95%CI), 50% expected prevalence ([@B20], [@B23]--[@B29]), and 2% design effect. The sample size calculated (plus an additional 10%) was 693 for staff and 748 for professors. Using a quota sampling method by school (professors) or department (staff), selections were made by convenience depending on presence in classrooms, offices, and recreational rooms. In all, the study sample comprised 499 staff and 736 professors.

Data collection
---------------

The interviewers presented themselves to the professors and staff, and described in detail the study's aims, risks, and benefits, in addition to its informed consent process. Subjects who agreed to participate signed consent forms. Interviews proceeded and survey forms were completed for each participant. Two separate anonymous survey forms were used for data collection, one per group, and later combined for analysis. The information collected was the same for both surveys. Data collection took place over a 2-month period. The surveys were composed of 14 closed- and open-ended questions that collected general data such as age, sex, school, and department, as well as information related to CHIKV infection: clinical manifestations, acute phase duration, diagnosis, treatment, and medical attention. The inclusion criteria were: professors and staff who were active at the time of the survey, were present in the work place when surveys were distributed, and had voluntarily accepted participation in the interviews.

Data management and analysis
----------------------------

Data were entered into a combined database in Microsoft Excel™ (Microsoft Corp., Redmond, Washington, United States), and statistical analyses were carried out using STATA^®^ version 13 (Stata Corp LP, College Station, Texas, United States). Univariate analyses were performed to observe the variable distribution and to quantify both acute and chronic manifestations from suspected CHIKV infection. Bivariate analyses were performed to explore the potential relationships between CHIKV infection and exposure variables such as age, sex, and length of the acute phase. Separate and combined analyses for professors and staff were performed. Analysis was primarily focused on descriptive statistics and frequency tables, with chi-squared tests performed to assess significance. Due to the cross-sectional nature of the study, prevalence ratios (PR) were used as the effect measure of interest. Age was converted into a three-level categorical variable and acute phase duration was dichotomized around a cut-off point of 9 days. For outcome variables, reported CHIKV infection and clinical manifestations were considered, all of which were binary based on presence. The study specifically investigated arthralgia, headache, myalgia, and edema as these were the most commonly reported chronic effects. The proportion distribution of each effect in the acute and chronic phases was reported.

RESULTS
=======

The total study population was 1 235 individuals, of which 736 were professors and 499 staff. Of the total, 57% were male, or more specifically, 63% of professors and 47% of staff. The age range was 18 -- 84 years (mean 45; standard deviation \[SD\] = 12.1); among professors, 24 -- 84 years (mean 50; SD = 9.8) and staff, 18 -- 78 years (mean 38; SD = 11.9) ([Table 1](#tbl1){ref-type="table"}).

###### Demographic characteristics of professors and staff surveyed in a study of chikungunya at a university in Santo Domingo, Dominican Republic, 2014

  Variable                     Total (*n* = 1 235)   Professors (*n* = 736)   Staff (*n* = 499)                   
  ---------------------------- --------------------- ------------------------ ------------------- ------- ------- -------
  Sex                                                                                                              
    Female                     531                   43.00                    269                 36.55   262     52.51
    Male                       704                   57.00                    467                 63.45   237     47.49
  Age                                                                                                              
    Mean, standard deviation   45.26                 12.13                    49.99               9.82    38.33   11.87
  Age category                                                                                                     
    \< 36 years                281                   22.85                      42                5.75    239     47.90
    36 -- 50 years             507                   41.22                    328                 44.87   179     35.87
    \> 50 years                442                   35.93                    361                 49.38     81    16.23

***Source:*** Prepared by the authors using study data.

Among those reporting suspected CHIKV infection, 54% were male, or more specifically 60% of professors and 48% of staff. This group was 18 -- 78 years of age (mean 44; SD = 12.3), with professors having a higher median age of 50 years (SD = 9.6) and staff having a lower median age of 38 years (SD = 11.7). In participants reporting suspected CHIKV infection, 38% were diagnosed by a doctor. Staff reported a higher proportion of diagnoses by a doctor than professors, 50% and 27%, respectively ([Table 2](#tbl2){ref-type="table"}).

###### Demographic characteristics and outcomes of chikungunya virus infection among professors and staff reporting infection at a university in the Dominican Republic, 2014

  Variable                     Both (*n* = 610)   Professors (*n* = 304)   Staff (*n* = 306)                   
  ---------------------------- ------------------ ------------------------ ------------------- ------- ------- -------
  Sex                                                                                                           
    Female                     282                46.23                    123                 40.46   159     51.96
    Male                       328                53.77                    181                 59.54   147     48.04
  Age                                                                                                           
    Mean, standard deviation   44.25              12.29                    50.38               9.61    38.19   11.65
  Age category                                                                                                  
    \< 36 years                167                27.42                    18                  5.94    149     48.69
    36 -- 50 years             237                38.92                    128                 42.24   109     35.62
    \> 50 years                205                33.66                    157                 51.82   48      15.69
  Diagnosed by                                                                                                  
    Self                       358                58.69                    207                 68.09   151     49.35
    Doctor                     234                38.36                    82                  26.97   152     49.67
    Neighbor/other             12                 1.97                     10                  3.29    2       0.65
  Acute effects                                                                                                 
    Arthralgia                 567                92.95                    275                 90.46   292     95.42
    Fever                      561                91.97                    278                 91.45   283     92.48
    Myalgia                    466                76.39                    196                 64.47   270     88.24
    Headache                   415                68.03                    178                 58.55   237     77.45
    Rash                       362                59.34                    154                 50.66   208     67.97
    Chills                     269                44.10                    110                 36.18   159     51.96
    Edema                      236                38.69                    106                 34.87   129     42.16
    Retroocular pain           176                28.85                    53                  17.43   123     40.20
    Nausea                     136                22.30                    39                  12.83   97      31.70
    Abdominal pain             110                18.03                    33                  10.86   77      25.16
    Bloodshot eyes             81                 13.28                    25                  8.22    56      18.30
    Vomiting                   61                 10.00                    16                  5.26    45      14.71
  Length of time                                                                                                
    \< 9 days                  450                73.77                    221                 72.70   229     74.84
    ≥ 9 days                   160                26.23                    83                  27.30   77      25.16
  Chronic effects                                                                                               
    Arthralgia                 293                48.03                    139                 45.72   154     50.33
    Edema                      49                 8.03                     34                  11.18   15      4.90
    Myalgia                    40                 6.56                     15                  4.93    25      8.17
    Headache                   18                 2.95                     5                   1.64    13      4.25
    Abdominal pain             11                 1.80                     4                   1.32    7       2.29
    Retroocular pain           7                  1.15                     4                   1.32    3       0.98
    Fever                      6                  0.98                     4                   1.32    2       0.65
    Rash                       6                  0.98                     5                   1.64    1       0.33
    Bloodshot eyes             4                  0.66                     4                   1.32    0       0.00
    Nausea                     3                  0.49                     3                   0.99    0       0.00
    Chills                     3                  0.49                     2                   0.66    1       0.33
    Vomiting                   1                  0.16                     1                   0.33    0       0.00

***Source***: Prepared by the authors using study data.

Of those who completed the survey, 610 (49%) reported suspected infection, including 304 (41%) professors and 306 (61%) staff. The proportion of staff that reported suspected infection by CHIKV was greater than that of professors, and this was statistically significant (*P* \< 0.001). It was also observed that the proportion in females was significantly higher than in males, 53% and 47%, respectively (*P* = 0.023). Furthermore, the proportion of younger subjects (\< 36 years of age) with CHIKV infection was significantly higher than that of older subjects (\> 50 years of age) at 60% versus 46%, respectively (*P* \< 0.001) ([Table 3](#tbl3){ref-type="table"}).

###### Proportion of reported CHIKV infection by group, sex, and age category in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

  Variable                     Infection (*n* = 610)   No infection (*n* = 623)   P             
  ---------------------------- ----------------------- -------------------------- ----- ------- ----------
  Overall (*n* = 1 235)        610                     49.39                      623   50.45    
  Staff (*n* = 499)            306                     61.32                      191   38.28   \< 0.001
  Professors (*n* = 736)       304                     41.30                      432   58.70    
  Sex                                                                                            
  Female (*n* = 531)           282                     53.11                      248   46.70   0.023
  Male (*n* = 704)             328                     46.59                      375   53.27    
  Age category                                                                                   
  \< 36 years (*n* = 280)      167                     59.64                      113   40.36   0.001
  36 -- 50 years (*n* = 506)   237                     46.84                      269   53.16    
  \> 50 years (*n* = 442)      205                     46.38                      237   53.62    

***Source:*** Prepared by the authors using study data.

The acute phase duration was reported to be less than 9 days in 74% of participants. The clinical manifestations most reported in the acute phase were (in decreasing order): arthralgia (93%), fever (92%), myalgia (76%), headache (68%), and rash (59%). Staff reported a higher proportion of all of these effects than professors. 53% of participants reported that at least one effect endured past the acute phase (not shown). The manifestations most reported in the chronic phase were (in decreasing order): arthralgia (48%), edema (8%), myalgia (7%), headache (3%) and abdominal pain (2%) ([Table 2](#tbl2){ref-type="table"}).

Among the reported acute effects, females were significantly more likely than males to report headache (*P* = 0.008) and edema (*P* \< 0.001). A significant relationship between younger age and reported headache (*P* = 0.005) was observed, with a higher proportion in those less than 36 years and 36 -- 50 years of age, than among those more than 50 years of age. Further, the authors observed that a longer acute phase duration (9 days or greater) was significantly associated with reported myalgia (*P* = 0.006) ([Table 4a](#tbl4a){ref-type="table"}).

###### Proportion distribution of acute manifestations by sex, age, and acute phase length in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

  Variable                     Acute                                                                                                                                   
  ---------------------------- ------- ------- ---- ------ ------- ----- ------- ----- ------- ------- ----- ------- ----- ------- ------- ----- ------- ----- ------- ----------
  Total (*n* = 610)                                                                                                                                                     
  Female (*n* = 282)           267     94.68   15   5.32   0.122   207   73.40   75    26.60   0.008   214   75.89   68    24.11   0.785   141   50.00   141   50.00   \< 0.001
  Male (*n* = 328)             300     91.46   28   8.54           208   63.41   120   36.59           252   76.83   76    23.17           94    28.66   234   71.34    
  \> 50 years (*n* = 205)      188     91.71   17   8.29   0.696   126   61.46   79    38.54   0.005   154   75.12   51    24.88   0.301   90    43.90   115   56.10   0.146
  36 -- 50 years (*n* = 237)   222     93.67   15   6.33           160   67.51   77    32.49           177   74.68   60    25.32           87    36.71   150   63.29    
  \< 36 years (*n* = 167)      156     93.41   11   6.59           129   77.25   38    22.75           135   80.84   32    19.16           58    34.73   109   65.27    
  ≥ 9 days (*n* = 160)         145     90.63   15   9.37   0.181   110   68.75   50    31.25   0.821   135   84.38   25    15.62   0.006   72    45.00   88    55.00   0.050
  \< 9 days (*n* = 450)        422     93.78   28   6.22           305   67.78   145   32.22           331   73.56   119   26.44           163   36.22   287   63.78    

Among the reported chronic effects, the study results show that females were significantly more likely to report arthralgia (*P* \< 0.001) and edema (*P* \< 0.001) than males. Also, individuals more than 50 years of age were significantly more likely to report chronic arthralgia (*P* = 0.003) and chronic edema (*P* = 0.001) than individuals in both younger age groups. Additionally, a significant relationship was observed between a longer duration of the acute phase and both chronic myalgia (*P* = 0.041) and chronic edema (*P* = 0.037) ([Table 4b](#tbl4b){ref-type="table"}).

###### Proportion distribution of chronic manifestations by sex, age, and acute phase length in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

  Variable                     Chronic                                                                                                                                    
  ---------------------------- --------- ------- ----- ------- ---------- ---- ------ ----- ------- ------- ---- ------- ----- ------- ------- ---- ------- ----- ------- ----------
  Total (*n* = 610)                                                                                                                                                        
  Female (*n* = 282)           158       56.03   124   43.97   \< 0.001   9    3.19   273   96.81   0.745   24   8.51    258   91.49   0.071   39   13.83   243   86.17   \< 0.001
  Male (*n* = 328)             135       41.16   193   58.84              9    2.74   319   97.26           16   4.88    312   95.12           10   3.05    318   96.95    
  \> 50 years (*n* = 205)      110       53.66   95    46.34   0.003      8    3.90   197   96.10   0.540   18   8.78    187   91.22   0.291   28   13.66   177   86.34   0.001
  36 -- 50 years (*n* = 237)   121       51.05   116   48.95              5    2.11   232   97.89           13   5.49    224   94.51           13   5.49    224   94.51    
  \< 36 years (*n* = 167)      62        37.13   105   62.87              5    2.99   162   97.01           9    5.39    158   94.61           8    4.79    159   95.21    
  ≥ 9 days (*n* = 160)         87        54.38   73    45.62   0.062      3    1.88   157   98.12   0.349   16   10.00   144   90.00   0.041   19   11.88   141   88.12   0.037
  \< 9 days (*n* = 450)        206       45.78   244   54.22              15   3.33   435   96.67           24   5.33    426   94.67           30   6.67    420   93.33    

***Source:*** Prepared by the authors using study data.

The results regarding acute effects show that females had a significantly higher (73% vs. 63%) prevalence of headache (PR = 1.16; 95% CI: 1.04 -- 1.29) and a significantly higher (50% vs. 29%) prevalence of edema (PR = 1.74; 95% CI: 1.43 -- 2.14) than males. Compared to subjects less than 36 years of age, those more than 50 years (PR = 0.80; 95% CI: 0.69 -- 0.91) had a significantly lower (61% vs. 77%) prevalence of headache. Those 36 -- 50 years of age (PR = 0.87; 95% CI: 0.77 -- 0.99) had a significantly lower (68% vs. 77%) prevalence of headache. Moreover, participants with acute phase symptoms of 9 days or greater had a significantly higher (84% vs. 74%) proportion of myalgia (PR = 1.15; 95%CI: 1.04 -- 1.26) ([Table 4a](#tbl4a){ref-type="table"} and [Table 5](#tbl5){ref-type="table"}).

###### Association between clinical manifestations and sex, age and acute phase length, in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

  Variable                     Acute      Chronic                                                                                              
  ---------------------------- ---------- --------- -------------- ------- ------------ -------------- ----- ------ -------------- ---- ------ --------------
  Total (*n* = 610)                                                                                                                             
  Sex                          Headache   Edema     Arthralgia     Edema                                                                       
  Female (*n* = 282)           207        1.16      (1.04, 1.29)   141     1.74         (1.43, 2.14)   158   1.36   (1.15, 1.61)   39   4.54   (2.47, 8.33)
  Male (*n* = 328)             208        1.00                     94      1.00                        135   1.00                  10   1.00    
  Age category                 Headache                                    Arthralgia   Edema                                                  
  \> 50 years (*n* = 205)      126        0.80      (0.69, 0.91)   ...     ...          ...            110   1.45   (1.15, 1.81)   28   2.85   (1.40, 5.83)
  36 -- 50 years (*n* = 237)   160        0.87      (0.77, 0.99)   ...     ...          ...            121   1.38   (1.10, 1.72)   13   1.15   (0.49, 2.70)
  \< 36 years (*n* = 167)      129        1.00                     ...     ...          ...            62    1.00                  8    1.00    
  Acute phase length           Myalgia                                     Myalgia      Edema                                                  
  ≥ 9 days (*n* = 160)         135        1.15      (1.04, 1.26)   ...     ...          ...            16    1.97   (1.02, 3.83)   19   1.89   (1.03, 3.47)
  \< 9 days (*n* = 450)        331        1.00                     ...     ...          ...            24    1.00                  30   1.00    

PR = prevalence rate ratio.

95% Confidence Interval.

***Source:*** Prepared by the authors using study data.

Among the reported chronic manifestations, females had a significantly higher (56% vs. 41%) prevalence of chronic arthralgia (PR = 1.36; 95%CI: 1.15 -- 1.61) and a significantly higher (14% vs. 3%) prevalence of chronic edema (PR = 4.54; 95%CI: 2.47 -- 8.33) than males. In comparison to the subjects less than 36 years of age, those greater than 50 (PR = 1.45; 95%CI: 1.15 -- 1.81) had a significantly higher (54% vs. 37%) prevalence of chronic arthralgia and those 36 -- 50 years of age (PR = 1.38; 95%CI: 1.10 -- 1.72) had a significantly higher (51% vs. 37%) prevalence of chronic arthralgia. Those more than 50 years of age (PR = 2.85, 95%CI: 1.40 -- 5.83) also had a significantly higher (14% vs. 5%) prevalence of chronic edema than those less than 36 years. Additionally, participants with acute phase symptoms 9 days or greater had a significantly higher (10% vs. 5%) prevalence of chronic myalgia (PR = 1.97; 95%CI: 1.02 -- 3.83) and a significantly higher (12% vs. 7%) prevalence of chronic edema (PR = 1.89; 95%CI: 1.03 -- 3.47) ([Table 4b](#tbl4b){ref-type="table"} and [Table 5](#tbl5){ref-type="table"}).

DISCUSSION
==========

Although the 2014 outbreak in the Dominican Republic appears to have ceased, research must be carried out to better understand the prevalence and risk factors of CHIKV infection and its associated clinical manifestations. This study examines the demographics and clinical profile of university personnel reporting CHIKV infection during the recent epidemic. It is our hope that its findings can promote enhanced prevention, diagnosis, and treatment of CHIKV infection, as well as encourage further population-based prevalence studies of CHIKV in the Region.

The prevalence of reported CHIKV infection in the study sample appears to reflect that of prior epidemics ([@B19], [@B23]--[@B27]). The prevalence was estimated to be 35% and 53% in the 2006 outbreaks in La Reunión (Martinique; 19, 23 -- 25) and Kerala (India; 26) respectively. This frequent occurrence of infection is likely reflective of the virus infectivity and pathogenicity, as well as the lack of immunity in the Dominican Republic (due to its recent emergence in the Americas).

In participants who reported suspected CHIKV infection, rates of acute clinical manifestations were observed to be comparable to other studies, with some minor differences. As expected, arthralgia and fever were the two most common symptoms ([@B28]). This matches the standard case definition, but these symptoms may have been under-reported due to recall bias, especially fever since it tends to be less distinct. The study sample reported myalgia more frequently than the 50% -- 60% prevalence reported in various other studies ([@B27], [@B29]). This is a frequently observed symptom after infection with an alphavirus, which has a tropism to muscle cells where it can replicate persistently ([@B6]). Additionally, the prevalence of headache was within the typical range ([@B26], [@B27], [@B29]), while rash was reported at a slightly higher rate than the 40% -- 50% prevalence in other studies ([@B12], [@B26], [@B27], [@B30]).

We also found that a majority of participants who reported infection experienced at least one symptom that persisted beyond the acute phase. While our survey did not specify a particular timeframe for chronic manifestations, the results are comparable to prior CHIKV outbreaks, for which studies reported that 73.6% and 57.0% of subjects had rheumatic symptoms at 1-month and 15-months post-diagnosis, respectively ([@B26], [@B31]). Since chronic manifestations tend to be more common in individuals with comorbidities and concurrent infections, this could potentially explain the slightly lower prevalence of chronic manifestations reported in our sample of university personnel.

As expected, arthralgia was by far the most common chronic symptom reported ([@B19], [@B26]--[@B29]). The high prevalence of chronic arthralgia can likely be explained by adaptive immune responses that promote the persistence of a high CHIKV viral load in joint-associated tissues ([@B32]). Patients with persistent arthralgia have been observed to have higher platelet counts and reduced liver enzyme levels than patients with faster recovery ([@B19]). The pathogenesis of joint pain from CHIKV infection is not well understood, but research has pointed towards older age, acute pain severity, and presence of comorbid arthralgia as factors promoting chronicity ([@B31]).

The high prevalence of chronic arthralgia observed is meaningful due to its reflection of the ongoing disease burden and costs resulting from this large epidemic in Santo Domingo, a major Caribbean city. A recent cohort study in Tolima (Colombia), site of a large outbreak in 2014--2015, found that about half of those with CHIKV infection experienced chronic arthralgia ([@B33]). In a smaller cohort study published in a different area of Colombia, the prevalence was even higher. Further research should be conducted in the Dominican Republic and other Latin American countries to determine the impact and timescale of chronic arthralgia among the general population, as well as potential measures to prevent its associated morbidity.

Additionally, the study results revealed a significantly higher prevalence of CHIKV infection in females and in younger subjects. The *Dirección General de Epidemiología* (Directorate General of Epidemiology, Santo Domingo; DIGEPI) reported preliminary case data from the town of San Gregorio de Nigua in March 2014 ([@B34]). This data showed a similar proportion of CHIKV infection in females and males, and a peak prevalence in adolescents 15 -- 19 years of age. The higher proportion of CHIKV infection observed in females and younger subjects in our study may be linked to increased outdoor exposures. This may be an important finding and demonstrate differences in symptomatic illness among population groups in the Dominican Republic. Alternatively, the finding could be linked to recall bias or inaccurate diagnosis. More research into the demographic variability between outbreaks could provide valuable information.

Finally, in our bivariate analyses, chronic arthralgia and chronic edema were significantly related to female sex and older age. We also observed a significantly higher prevalence of chronic edema and chronic myalgia in those who reported a longer phase of acute symptoms. These findings mirror the results of two retrospective studies following the Reunion Island outbreak ([@B19], [@B31]), which reported that patients with persistent arthralgia or rheumatic symptoms had a higher mean age and were more likely to be female. These studies serve as a valuable point of comparison, but had much smaller sample sizes (56 and 84 patients with persistent rheumatic symptoms, respectively). The aforementioned study in Colombia also found a higher prevalence of chronic arthralgia in females and older individuals ([@B33]). A potential explanation for the increased prevalence of symptoms in females is the tendency to have higher rates of headaches, edema, and joint or muscle pain during pregnancy or post-menopause ([@B35]). It could also be linked to differences in age between the male and female participants; we found that females in our study were younger \[not reported\].

The principal strength of our study was the large sample size of 1 236 individuals. Sampling from a large public university population is likely to promote greater generalizability of the findings due to the representative nature of this population. Post-outbreak studies to observe infection and clinical manifestation prevalence in the Dominican Republic and the Americas, as well as risk factors related to poorer outcomes, have not been sufficiently studied to date. This study also investigated reported chronic manifestations, which have been largely unexplored in the CHIKV epidemic in the Americas, and identified factors linked to increased prevalence.

Limitations
-----------

Even after taking into account the methodological criteria applied in the design stage, the results described above should be analyzed carefully, while keeping in mind the study limitations. Similar to most studies of CHIKV infection, past and current symptoms were self-reported without laboratory confirmation, which may have led to over-or under-estimation of the symptom prevalence. The survey was also carried out months after infection in most cases, which could have promoted recall bias and magnification of the symptoms. In [Tables 4](#tbl4a){ref-type="table"} and [5](#tbl5){ref-type="table"}, it is also clear that the significance of the results was affected by the sample size in each category. For example, the rarity of chronic headaches made it more difficult for a significant relationship to be observed. Additionally, the surveys would have been more informative if they contained supplementary questions on factors such as socioeconomic status, educational level, recent pregnancy, and concurrent illness. Inclusion of university students in the analysis would also have provided additional information.

Conclusions
-----------

To the authors' knowledge, this is the first population-based CHIKV infection prevalence study in the Dominican Republic, and the first to explore the prevalence of the clinical manifestations of CHIKV infection in university professors and staff. We observed a high prevalence of CHIKV infection and chronic arthralgia, as well as various significant relationships among key risk factors and clinical manifestations of CHIKV infection. After comparisons were performed, we observed that our findings generally mirror the results of studies from other outbreaks, such as that of Reunion Island.

This research is important in highlighting the impact of CHIKV infection on the Caribbean and the Region of the Americas as a whole, and allowing for improved characterization of resulting clinical manifestations. Additional longitudinal research and population-based prevalence studies could provide further insight into these effects.
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